5-乙氧基-2-甲基苯胺 | 75785-11-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 5-乙氧基-2-甲基苯胺
• 英文名称: 5-ethoxy-2-methylaniline
• 英文别名: 5-ethoxy-2-methyl-aniline；5-Aethoxy-2-methyl-anilin；5-(ethyloxy)-2-methylaniline；5-ethoxy-2-methylbenzenamine；2-amino-4-ethoxytoluene
• CAS: 75785-11-4
• 化学式: C₉H₁₃NO
• 分子量: 151.208
• InChiKey: BDVOFUMMFBMIBN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-乙氧基-2-甲基苯胺 在 potassium nitrososulfonate 作用下， 生成 2-ethoxy-5-methyl-[1,4]benzoquinone
  参考文献：
  名称：

  Teuber; Hasselbach, Chemische Berichte, 1959, vol. 92, p. 674,688

  摘要：

  DOI：
• 作为产物：
  描述：

  4-乙氧基-1-甲基-2-硝基苯 在 palladium on activated charcoal 、 甲酸铵 作用下， 以 乙醇 为溶剂， 反应 0.5h， 以98%的产率得到5-乙氧基-2-甲基苯胺
  参考文献：
  名称：

  Discovery, Optimization, and Biological Evaluation of 5-(2-(Trifluoromethyl)phenyl)indazoles as a Novel Class of Transient Receptor Potential A1 (TRPA1) Antagonists

  摘要：

  A high throughput screening campaign identified 5-(2-chlorophenyl)indazole compound 4 as an antagonist of the transient receptor potential A1 (TRPA1) ion channel with IC50 = 1.23 μM. Hit to lead medicinal chemistry optimization established the SAR around the indazole ring system, demonstrating that a trifluoromethyl group at the 2-position of the phenyl ring in combination with various substituents at the 6-position of the indazole ring greatly contributed to improvements in vitro activity. Further lead optimization resulted in the identification of compound 31, a potent and selective antagonist of TRPA1 in vitro (IC50 = 0.015 μM), which has moderate oral bioavailability in rodents and demonstrates robust activity in vivo in several rodent models of inflammatory pain.

  DOI：

  10.1021/jm401986p

文献信息

• Quinoline derivatives or salt thereof and remedy for cardiac diseases
  申请人：Kowa Co., Ltd.

  公开号：US05576324A1

  公开（公告）日：1996-11-19

  A quinoline derivative represented by general formula (1), a medicinally acceptable salt thereof, and a remedy for cardiac diseases containing the same: ##STR1## [wherein ring A represents a furan, dihydrofuran or dioxolane ring, and R.sup.1 represents an aminoalkyl group]. The compound (1) has a positively inotropic effect on myocardia and an antiarrhythmic effect, and can dilate blood vessels without extremely increasing the heart rate. Therefore, a remedy for cardiac diseases containing the same as the active ingredient is remarkably useful for treating cardiac insufficiency, arrhythmia, and so forth.

  一种以一般式（1）表示的喹啉衍生物，其药学上可接受的盐，以及含有该物质的心脏疾病疗法：##STR1## [其中环A代表呋喃、二氢呋喃或二氧杂环戊烷环，R.sup.1代表氨基烷基基团]。化合物（1）对心肌具有正性肌力作用和抗心律失常作用，并且可以扩张血管而不会极大增加心率。因此，含有该物质作为活性成分的心脏疾病疗法对治疗心脏功能不全、心律失常等疾病非常有用。
• Indole derivatives, salts thereof, and congestive heart failure
  申请人：Kowa Co., Ltd.

  公开号：US05510366A1

  公开（公告）日：1996-04-23

  An indole derivative represented by formula (1), ##STR1## wherein A is a group ##STR2## wherein R.sup.10 is hydrogen or lower alkyl, dotted lines may optionally be present, and R.sup.1 -R.sup.9 represents various substitutional groups. The compound (1) exhibits a positive inotropic action on cardiac muscle, an anti-arrhythmic action, and a vasodilation action without increasing the heart rate. A heart affection therapeutic agent comprising this compound as an effective component is extremely effective for treating heart failures and arrhythmia.

  公式（1）所代表的吲哚衍生物，其中A是一个基团，其中R.sup.10是氢或较低的烷基，可能存在虚线，而R.sup.1-R.sup.9代表各种取代基团。化合物（1）对心脏肌肉具有正性肌力作用，具有抗心律失常作用，并且具有扩血管作用而不增加心率。包含该化合物作为有效成分的心脏疗法药剂对治疗心力衰竭和心律失常非常有效。
• SPIROCHROMANON DERIVATIVES
  申请人：Iino Tomoharu

  公开号：US20090270436A1

  公开（公告）日：2009-10-29

  The invention relates to a compound of a general formula (I): wherein Ar1 represents a group formed from an aromatic ring selected from a group consisting of benzene, pyrazole, isoxazole, pyridine, indole, 1H-indazole, 1H-furo[2,3-c]pyrazole, 1H-thieno[2,3-c]pyrazole, benzimidazole, 1,2-benzisoxazole, imidazo[1,2-a]pyridine, imidazo[1,5-a]pyridine and 1H-pyrazolo[3,4-b]pyridine, having Ar2, and optionally having one or two or more substituents selected from R3: R1 and R2 each independently represent a hydrogen atom, a halogen atom, a cyano group, a C2-C6 alkenyl group, a C1-C6 alkoxy group, a C2-C7 alkanoyl group, a C2-C7 alkoxycarbonyl group, an aralkyloxycarbonyl group, a carbamoyl-C1-C6 alkoxy group, a carboxy-C2-C6 alkenyl group, or a group of -Q1-N(Ra)-Q2-Rb; or a C1-C6 alkyl group optionally having a substituent; or an aryl or heterocyclic group optionally having a substituent; or a C1-C6 alkyl group or a C2-C6 alkenyl group having the aryl or heterocyclic group; T and U each independently represent a nitrogen atom or a machine group; and V represents an oxygen atom or a sulfur atom. The compound of the invention is useful as therapeutical agents for various ACC-related diseases.

  本发明涉及一种通式（I）的化合物：其中Ar1代表从苯，吡唑，异噁唑，吡啶，吲哚，1H-吲唑，1H-呋喃[2,3-c]吡唑，1H-噻吩[2,3-c]吡唑，苯并咪唑，1,2-苯并异噁唑，咪唑并[1,2-a]吡啶，咪唑并[1,5-a]吡啶和1H-吡唑并[3,4-b]吡啶中选择的芳香环形成的基团，具有Ar2，并且可选地具有一个、两个或更多从R3中选择的取代基：R1和R2各自独立地表示氢原子，卤素原子，氰基，C2-C6烯基基团，C1-C6烷氧基团，C2-C7烷酰基基团，C2-C7烷氧羰基基团，芳基烷氧羰基基团，氨基-C1-C6烷氧基团，羧基-C2-C6烯基基团或-Q1-N（Ra）-Q2-Rb基团；或者是一个可选具有取代基的C1-C6烷基基团；或者是一个可选具有取代基的芳基或杂环基团；或者是一个具有芳基或杂环基团的C1-C6烷基或C2-C6烯基基团；T和U各自独立地表示氮原子或机器基团；V表示氧原子或硫原子。本发明的化合物可用作治疗各种ACC相关疾病的治疗剂。
• Spirochromanon derivatives
  申请人：MSD K.K.

  公开号：US08138197B2

  公开（公告）日：2012-03-20

  The invention relates to a compound of a general formula (I): wherein Ar1 represents a group formed from an aromatic ring selected from a group consisting of benzene, pyrazole, isoxazole, pyridine, indole, 1H-indazole, 1H-furo[2,3-c]pyrazole, 1H-thieno[2,3-c]pyrazole, benzimidazole, 1,2-benzisoxazole, imidazo[1,2-a]pyridine, imidazo[1,5-a]pyridine and 1H-pyrazolo[3,4-a]pyridine, having Ar2, and optionally having one or two or more substituents selected from R3; R1 and R2 each independently represent a hydrogen atom, a halogen atom, a cyano group, a C2-C6 alkenyl group, a C1-C6 alkoxy group, a C2-C7 alkanoyl group, a C2-C7 alkoxycarbonyl group, an aralkyloxycarbonyl group, a carbamoyl-C1-C6 alkoxy group, a carboxy-C2-C6 alkenyl group, or a group of -Q1-N(Ra)-Q2-Rb; or a C1-C6 alkyl group optionally having a substituent; or an aryl or heterocyclic group optionally having a substituent; or a C1-C6 alkyl group or a C2-C6 alkenyl group having the aryl or heterocyclic group; T and U each independently represent a nitrogen atom or a methine group; and V represents an oxygen atom or a sulfur atom. The compound of the invention is useful as therapeutical agents for various ACC-related diseases.

  本发明涉及一种通式(I)的化合物： 其中Ar1代表由苯、吡唑、异氧唑、吡啶、吲哚、1H-吲唑、1H-呋喃[2,3-c]吡唑、1H-噻吩[2,3-c]吡唑、苯并咪唑、1,2-苯并异氧唑、咪唑并[1,2-a]吡啶、咪唑并[1,5-a]吡啶和1H-吡唑并[3,4-a]吡啶中选取的芳香环组成的基团，具有Ar2，并可选地具有一个或两个或更多的取代基，所述取代基选自R3；R1和R2各自独立地代表氢原子、卤素原子、氰基、C2-C6烯基基团、C1-C6烷氧基团、C2-C7烷酰基基团、C2-C7烷氧羰基基团、芳基烷氧羰基基团、氨基-C1-C6烷氧基团、羧基-C2-C6烯基基团，或-Q1-N(Ra)-Q2-Rb的基团；或者是具有取代基的C1-C6烷基基团；或者是具有取代基的芳基或杂环基团；或者是具有芳基或杂环基团的C1-C6烷基或C2-C6烯基基团；T和U各自独立地代表氮原子或甲基基团；V代表氧原子或硫原子。本发明的化合物可用作治疗各种与ACC相关的疾病的治疗剂。
• Heterocyclic Non-Peptide GNRH Antagonists
  申请人：Showell Graham Andrew

  公开号：US20090209522A1

  公开（公告）日：2009-08-20

  A compound of formula (I): wherein either B is absent and A and Z are the same or different and are each hydrogen, halogen, alkyl, hydroxy, alkoxy, —CN, —C(R c ) 2 OH, —N(R d )C(═X)R c , —C(═X)N(R c )(R d ), —S(O) m —R c , —N(R c )(R d )S(O) 2 , —S(O) 2 N(R c )(R d ), —N(R c ) 2 , aryl optionally substituted with R a or —O-aryl optionally substituted with R a ; or B is present and is —(CH 2 ) n —, —C(R b ) 2 — or —O—, or B taken together with A or Z can be —C═C(R b )—, —C(R b )═C—, —CH 2 —CH(R b )— or —CH(R b )—CH 2 —; D is —O— or —S(O) m′ —; E is a bond or is —(CH 2 ) n —, —N(R d )—, —(CH 2 ) n N(R d )— or —N(R d )(CH 2 ) n —; F is —C(═X)—; G is —(CH 2 ) n —, —N(R d )—, —(CH 2 ) n N(R d )— or —N(R d )(CH 2 ) n ; J is a bond, —O—, —N(R C )C(═X)—, —C(═X)N(R c )—, —S(O) m′ —, —N(R c )S(O) m —, —S(O) n N(R c )—, —N(R c )— or —N(R g )(R h ); K is a bond, alkylene, cycloalkylene, cycloalkenylene, arylene, heterocycloalkylene, heterocycloalkylene or heteroarylene; and L is hydrogen or a terminal group; has therapeutic utility.

  化合物的化学式（I）：其中B可能不存在，而A和Z相同或不同，分别为氢、卤素、烷基、羟基、烷氧基、—CN、—C（Rc）2OH、—N（Rd）C（═X）Rc、—C（═X）N（Rc）（Rd）、—S（O）m—Rc、—N（Rc）（Rd）S（O）2、—S（O）2N（Rc）（Rd）、—N（Rc）2、取代为Ra的芳基或—O-取代为Ra的芳基；或B存在且为—（CH2）n—、—C（Rb）2—或—O—，或B与A或Z一起可以是—C═C（Rb）—、—C（Rb）═C—、—CH2—CH（Rb）—或—CH（Rb）—CH2—；D为—O—或—S（O）m′—；E为键或—（CH2）n—、—N（Rd）—、—（CH2）nN（Rd）—或—N（Rd）（CH2）n—；F为—C（═X）—；G为—（CH2）n—、—N（Rd）—、—（CH2）nN（Rd）—或—N（Rd）（CH2）n；J为键、—O—、—N（RC）C（═X）—、—C（═X）N（Rc）—、—S（O）m′—、—N（Rc）S（O）m—、—S（O）nN（Rc）—、—N（Rc）—或—N（Rg）（Rh）；K为键、烷基、环烷基、环烯基、芳基、杂环烷基、杂环烷基或杂芳基；L为氢或端基；具有治疗效用。